Vaccine Against Placental Malaria Ready to Start Human Tests
ExpreS2ion Biotechnologies, has announced the release by its partners at University of Copenhagen, of a vaccine candidate against the form of malaria that strikes pregnant women, for testing in humans. The vaccine candidate contains a malaria antigen made with ExpreS2ion’s proprietary protein expression technology, ExpreS2.
This vaccine candidate results from many years of research done by Professor Ali Salanti and his team at the Department of Immunology and Microbiology at the University of Copenhagen. This work is an example of how ExpreS2ion collaborates with its partners to enable advancement of promising vaccines.
Dr Charlotte Dyring, CEO of ExpreS2ion Biotechnologies, said: “This is a very important milestone for our company. The ExpreS2 system solved the protein expression challenge for this antigen that had failed to be expressed in alternative systems. More than 30 variants of the complex malaria antigen that forms part of this vaccine were produced by ExpreS2ion to enable Professor Salanti’s team to perform the needed tests to select the most promising vaccine candidate. A very robust production process for the antigen was developed by ExpreS2ion and transferred to a manufacturer for production of a batch performed under conditions necessary for human testing. We consider the collaboration with the University of Copenhagen an important success for ExpreS2ion: we have delivered on the needs of the project, and demonstrated again the power of our protein expression system ExpreS2 to deliver results seamlessly through development, from research to manufacturing under the stringent regulatory needs of GMP”.
“It is the first time that a university in Denmark has conceived and produced a vaccine, and this has only been achieved because of the very close cooperation within the consortium that includes ExpreS2ion and the University,” commented Professor Salanti. The work leading to the release of the testing lot of this vaccine has been funded by the Danish Advanced Technology Foundation (HTF, now Innovation Fund) the European Vaccine Initiative (EVI) and the Framework 7 European Union program.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance